Paul Edward Bing, M.D Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 21700 Kingsland Blvd, Suite 201, Katy, TX 77450 Phone: 281-398-7954 Fax: 281-578-4912 |
Dr. Qi-ming Zhu, D.O. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 21700 Kingsland Blvd, Ste 201, Katy, TX 77450 Phone: 281-398-7954 |
Jamal Adel Turki, M.D Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 20510 Walnut Canyon Dr, Katy, TX 77450 Phone: 713-820-5009 |
News Archive
New results from researchers at MedUni Vienna's Center for Pathobiochemistry and Genetics show that a protein called mTORC2, which is the target of newly developed cancer drugs, is not even active in colorectal cancer. mTORC2 activity was only found in certain immune cells, which actually need this protein to fight cancer cells.
Left ventricular function and exercise capacity increased, while the area of heart muscle damage shrank, in 18 patients given infusions of their own bone marrow stem cells up to eight years after a heart attack, according to a new study in the Nov. 1, 2005, issue of the Journal of the American College of Cardiology.
A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.
The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.
After the US Prostate Cancer Prevention Trial found cancer in many men with low levels of prostate specific antigen (PSA), many debated which PSA level should lead to a biopsy recommendation. The US Preventive Screening Task Force (USPSTF) recently concluded, amid considerable controversy, that the evidence does not support recommending PSA screening for men under 75 years old at all, because the risks outweigh the benefits.
› Verified 1 days ago